Category: 16506-27-7

Hemolytic crisis due to Covid-19 vaccination in a woman with cold agglutinin disease was written by Perez-Lamas, Lucia;Moreno-Jimenez, Gemma;Tenorio-Nunez, Maria C.;Velazquez-Kennedy, Kyra;Jimenez-Chillon, Carlos;Astibia-Mahillo, Beatriz;Nunez-Torron, Claudia;Garcia-Gutierrez, Valentin;Jimenez-Martin, Ana;Valles-Carboneras, Ana;Lopez-Jimenez, Javier F.. And the article was included in American Journal of Hematology in 2021.COA of Formula: C16H21Cl2N3O2 The following contents are mentioned in the article:

Hemolytic crisis due to Covid-19 vaccination in a woman with cold agglutinin disease, the patient was treated with prednisone 20 mg daily with improvement of the hemolytic parameters and Hb level to baseline values. This study involved multiple reactions and reactants, such as 4-(5-(Bis(2-chloroethyl)amino)-1-methyl-1H-benzo[d]imidazol-2-yl)butanoic acid (cas: 16506-27-7COA of Formula: C16H21Cl2N3O2).

4-(5-(Bis(2-chloroethyl)amino)-1-methyl-1H-benzo[d]imidazol-2-yl)butanoic acid (cas: 16506-27-7) belongs to imidazole derivatives. Imidazole is the basic core of some natural products such as histidine, purine, histamine and DNA based structures, etc. Among the different heterocyclic compounds, imidazole is better known due to its broad range of chemical and biological properties. This ring system is present in important biological building blocks, such as histidine and the related hormone histamine.COA of Formula: C16H21Cl2N3O2

Referemce:
Imidazole – Wikipedia,
Imidazole | C3H4N2 – PubChem

Effectiveness of ibrutinib as first-line therapy for chronic lymphocytic leukemia patients and indirect comparison with rituximab-bendamustine: Results of study on 486 cases outside clinical trials was written by Morabito, Fortunato;Tripepi, Giovanni;Del Poeta, Giovanni;Mauro, Francesca Romana;Reda, Gianluigi;Sportoletti, Paolo;Laurenti, Luca;Coscia, Marta;Herishanu, Yair;Bossio, Sabrina;Varettoni, Marzia;Murru, Roberta;Chiarenza, Annalisa;Visentin, Andrea;Condoluci, Adalgisa;Moia, Riccardo;Pietrasanta, Daniela;Loseto, Giacomo;Consoli, Ugo;Scortechini, Ilaria;Rossi, Francesca Maria;Zucchetto, Antonella;Al-Janazreh, Hamdi;Vigna, Ernesto;Martino, Enrica Antonia;Cassin, Ramona;D’Arrigo, Graziella;Galimberti, Sara;Rago, Angela;Angeletti, Ilaria;Biagi, Annalisa;Del Giudice, Ilaria;Bomben, Riccardo;Neri, Antonino;Fronza, Gilberto;Monti, Paola;Menichini, Paola;Olivieri, Jacopo;Cutrona, Giovanna;Rossi, Davide;Cuneo, Antonio;Di Raimondo, Francesco;Gaidano, Gianluca;Polliack, Aaron;Trentin, Livio;Foa, Robin;Ferrarini, Manlio;Gattei, Valter;Gentile, Massimo. And the article was included in American Journal of Hematology in 2021.SDS of cas: 16506-27-7 The following contents are mentioned in the article:

However, these biomarkers’ practical prognostic relevance in the era of new drugs remains an open issue. Results investigating the clin. impact of IB in the current clin. practice mainly focused so far on relapsedresistant (RR) patients. Here, we conducted a multicenter, retrospective study to ascertain the predictive and prognostic relevance of well-known biol. and clin. indicators in 165 patients treated with IB as first-line. This study involved multiple reactions and reactants, such as 4-(5-(Bis(2-chloroethyl)amino)-1-methyl-1H-benzo[d]imidazol-2-yl)butanoic acid (cas: 16506-27-7SDS of cas: 16506-27-7).

4-(5-(Bis(2-chloroethyl)amino)-1-methyl-1H-benzo[d]imidazol-2-yl)butanoic acid (cas: 16506-27-7) belongs to imidazole derivatives. Imidazole is a heterocyclic compound with a five-membered planar ring. It is amphoteric and highly polar. Imidazole also acts as a microtubule destabilizing agents and inhibits topoisomerase and Cytochrome P450 Family 26 Subfamily A Member 1 (CYP26A1) enzymes.SDS of cas: 16506-27-7

Referemce:
Imidazole – Wikipedia,
Imidazole | C3H4N2 – PubChem

Effectiveness of ibrutinib as first-line therapy for chronic lymphocytic leukemia patients and indirect comparison with rituximab-bendamustine: Results of study on 486 cases outside clinical trials was written by Morabito, Fortunato;Tripepi, Giovanni;Del Poeta, Giovanni;Mauro, Francesca Romana;Reda, Gianluigi;Sportoletti, Paolo;Laurenti, Luca;Coscia, Marta;Herishanu, Yair;Bossio, Sabrina;Varettoni, Marzia;Murru, Roberta;Chiarenza, Annalisa;Visentin, Andrea;Condoluci, Adalgisa;Moia, Riccardo;Pietrasanta, Daniela;Loseto, Giacomo;Consoli, Ugo;Scortechini, Ilaria;Rossi, Francesca Maria;Zucchetto, Antonella;Al-Janazreh, Hamdi;Vigna, Ernesto;Martino, Enrica Antonia;Cassin, Ramona;D’Arrigo, Graziella;Galimberti, Sara;Rago, Angela;Angeletti, Ilaria;Biagi, Annalisa;Del Giudice, Ilaria;Bomben, Riccardo;Neri, Antonino;Fronza, Gilberto;Monti, Paola;Menichini, Paola;Olivieri, Jacopo;Cutrona, Giovanna;Rossi, Davide;Cuneo, Antonio;Di Raimondo, Francesco;Gaidano, Gianluca;Polliack, Aaron;Trentin, Livio;Foa, Robin;Ferrarini, Manlio;Gattei, Valter;Gentile, Massimo. And the article was included in American Journal of Hematology in 2021.SDS of cas: 16506-27-7 The following contents are mentioned in the article:

However, these biomarkers’ practical prognostic relevance in the era of new drugs remains an open issue. Results investigating the clin. impact of IB in the current clin. practice mainly focused so far on relapsedresistant (RR) patients. Here, we conducted a multicenter, retrospective study to ascertain the predictive and prognostic relevance of well-known biol. and clin. indicators in 165 patients treated with IB as first-line. This study involved multiple reactions and reactants, such as 4-(5-(Bis(2-chloroethyl)amino)-1-methyl-1H-benzo[d]imidazol-2-yl)butanoic acid (cas: 16506-27-7SDS of cas: 16506-27-7).

4-(5-(Bis(2-chloroethyl)amino)-1-methyl-1H-benzo[d]imidazol-2-yl)butanoic acid (cas: 16506-27-7) belongs to imidazole derivatives. Imidazole is a heterocyclic compound with a five-membered planar ring. It is amphoteric and highly polar. Imidazole also acts as a microtubule destabilizing agents and inhibits topoisomerase and Cytochrome P450 Family 26 Subfamily A Member 1 (CYP26A1) enzymes.SDS of cas: 16506-27-7

Referemce:
Imidazole – Wikipedia,
Imidazole | C3H4N2 – PubChem

How I treat and prevent venous thrombotic complications in patients with lymphoma was written by Schmidt, Robert A.;Lee, Agnes Y. Y.. And the article was included in Blood in 2022.Quality Control of 4-(5-(Bis(2-chloroethyl)amino)-1-methyl-1H-benzo[d]imidazol-2-yl)butanoic acid The following contents are mentioned in the article:

Venous thromboembolism (VTE) is a common complication occurring in 5% to 10% of patients with lymphoma. As the complexity of lymphoma management has increased with novel therapies, so too has the treatment of VTE. Therapeutic options for the treatment of cancer-associated VTE have expanded from only warfarin and low-mol.-weight heparins (LMWHs) to include the direct oral anticoagulants (DOACs) apixaban, edoxaban and rivaroxaban. There have been no head-to-head trials comparing different DOACs in this setting, and randomized trials comparing a DOAC with LMWH dalteparin differ in trial design and results. Drug-drug interactions, drug-specific side effects, and patient selection are important considerations when prescribing anticoagulant therapy. In all patients, the relative risks of thrombosis and bleeding, the availability of the anticoagulant, and the life expectancy of the patient are vital elements in selecting the most appropriate anticoagulant (which can vary over time) for the individual patient. We describe the intricacies and challenges of treating thrombotic complications in patients with lymphoma with an emphasis on evidence and guideline-based care. This study involved multiple reactions and reactants, such as 4-(5-(Bis(2-chloroethyl)amino)-1-methyl-1H-benzo[d]imidazol-2-yl)butanoic acid (cas: 16506-27-7Quality Control of 4-(5-(Bis(2-chloroethyl)amino)-1-methyl-1H-benzo[d]imidazol-2-yl)butanoic acid).

4-(5-(Bis(2-chloroethyl)amino)-1-methyl-1H-benzo[d]imidazol-2-yl)butanoic acid (cas: 16506-27-7) belongs to imidazole derivatives. 1H-imidazole is an imidazole tautomer which has the migrating hydrogen at position 1. It is a conjugate base of an imidazolium cation. It is a conjugate acid of an imidazolide. It is a tautomer of a 4H-imidazole. Imidazole based anticancer drug find applications in cancer chemotherapy. It is used as buffer component for purification of the histidine tagged recombinant proteins in immobilized metal-affinity chromatography (IMAC).Quality Control of 4-(5-(Bis(2-chloroethyl)amino)-1-methyl-1H-benzo[d]imidazol-2-yl)butanoic acid

Referemce:
Imidazole – Wikipedia,
Imidazole | C3H4N2 – PubChem

Electrochemical determination of anticancer drug Bendamustine and its interaction with double strand DNA in the absence and presence of quercetin was written by Erol, Aylin;Akpinar, Fatma;Muti, Mihrican. And the article was included in Colloids and Surfaces, B: Biointerfaces in 2021.Synthetic Route of C16H21Cl2N3O2 The following contents are mentioned in the article:

Studies based on drug-DNA interactions, especially anticancer drug-DNA interactions, are of great importance for the method development. It is thought that single-use electrodes, which give fast, cheap and reproducible results, will make a great contribution to the chip technol. for the development of individual patient anal. in the future. It is known that antioxidants reduce carcinogenesis caused by oxidative stress with their radical scavenging effects. Literature shows that quercetin (QRCT) exhibits anticancer activity by preventing oxidative cell damage as an effective radical scavenger. In this study, Bendamustine (BND), an anticancer drug, which is used in different blood cancer types, was electrochem. determined and the toxicity degree was calculated by examining the interaction of the drug with DNA in the absence and presence of QRCT, which is the first examination in the literature. Limit of detection and quantification for BND was calculated as 6.0 and 20.0渭g/mL resp. by using the equation I = 0.029 x CBND+ 1.197, (R2 = 0.997). We found that QRCT prevents the interaction between BND and DNA because of its strong interaction with DNA. This study involved multiple reactions and reactants, such as 4-(5-(Bis(2-chloroethyl)amino)-1-methyl-1H-benzo[d]imidazol-2-yl)butanoic acid (cas: 16506-27-7Synthetic Route of C16H21Cl2N3O2).

4-(5-(Bis(2-chloroethyl)amino)-1-methyl-1H-benzo[d]imidazol-2-yl)butanoic acid (cas: 16506-27-7) belongs to imidazole derivatives. Imidazole is a heterocyclic compound with a five-membered planar ring. It is amphoteric and highly polar. Imidazole also acts as a microtubule destabilizing agents and inhibits topoisomerase and Cytochrome P450 Family 26 Subfamily A Member 1 (CYP26A1) enzymes.Synthetic Route of C16H21Cl2N3O2

Referemce:
Imidazole – Wikipedia,
Imidazole | C3H4N2 – PubChem

Management of Waldenstrom’s macroglobulinemia on the basis of cytogenetic abnormality was written by Sekiguchi, Naohiro. And the article was included in Ketsueki Naika in 2022.Application In Synthesis of 4-(5-(Bis(2-chloroethyl)amino)-1-methyl-1H-benzo[d]imidazol-2-yl)butanoic acid The following contents are mentioned in the article:

Indeed, in the last decade, the mol. pathogenesis of WM, such as chromosomal abnormalities, gene mutations, and signal transduction, has progressed rapidly, and new drugs, including BTK inhibitors, have been vigorously developed. While there are reports indicating that searching for chromosomal/genetic abnormalities at the time of diagnosis is highly significant in predicting the response rate and long-term prognosis in the therapeutic intervention of WM, in Japan, it is difficult to say that such searches are sufficiently performed in routine clin. practice. At present, there are no high-evidence-level clin. practice guidelines or prognostic models based on chromosomal/genetic abnormalities. It is hoped that in the next 10 years established a stratification of clin. practice based on chromosomal/genetic abnormalities in WM. In this article, the author like to explain the chromosomal/genetic abnormalities that can be detected by WM, and also discuss the prognostic significance of chromosomal/genetic abnormalities, proposed treatment algorithms based on chromosomal/genetic abnormalities, and issues, including my personal views. This study involved multiple reactions and reactants, such as 4-(5-(Bis(2-chloroethyl)amino)-1-methyl-1H-benzo[d]imidazol-2-yl)butanoic acid (cas: 16506-27-7Application In Synthesis of 4-(5-(Bis(2-chloroethyl)amino)-1-methyl-1H-benzo[d]imidazol-2-yl)butanoic acid).

4-(5-(Bis(2-chloroethyl)amino)-1-methyl-1H-benzo[d]imidazol-2-yl)butanoic acid (cas: 16506-27-7) belongs to imidazole derivatives. Many natural products, especially alkaloids, contain the imidazole ring. These imidazoles share the 1,3-C3N2 ring but feature varied substituents. Imidazole has been usedin the lysis, wash and elution buffer for the purification of histidine tagged Sonic Hedgehog(shh-N) protein, in elution buffer in stepwise gradient for the purification of histidine tagged aldo keto reductases using nickel affinity chromatography, as a component of homogenization buffer for the purification of phagosomal compartments from dendritic cells.Application In Synthesis of 4-(5-(Bis(2-chloroethyl)amino)-1-methyl-1H-benzo[d]imidazol-2-yl)butanoic acid

Referemce:
Imidazole – Wikipedia,
Imidazole | C3H4N2 – PubChem

Persistent viral shedding of severe acute respiratory syndrome coronavirus 2 after treatment with bendamustine and rituximab: A case report was written by Arai, Tatsuya;Mukai, Satoru;Kazama, Ryo;Ogawa, Yoshihiko;Nishida, Koji;Hatanaka, Kazuo;Gohma, Iwao. And the article was included in Journal of Infection and Chemotherapy in 2022.Related Products of 16506-27-7 The following contents are mentioned in the article:

Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) RNA is detectable in nasopharyngeal specimens for up to 12-20 days regardless of the presence of chronic diseases in patients. A case of prolonged SARS-CoV-2 infection that lasted for more than eight weeks was reported. The patient had persistent lymphopenia after receiving six cycles of bendamustine and rituximab (BR) therapy for follicular lymphoma; the last chemotherapy session was completed nine months before admission. The first nasopharyngeal specimen (NPS) for the SARS-CoV-2 polymerase chain reaction assay tested pos. for the N501Y variant five weeks before admission. The patient”s general and respiratory conditions gradually worsened; therefore admitted in the hospital, and the same SARS-CoV-2 variant was subsequently identified on admission. Treatment for coronavirus disease was initiated, and the patien’s condition improved; however, the NPS tested pos. on day 15. The patient was discharged on day 28 and was instructed to isolate at home for a month. Hence, possible prolonged SARS-CoV-2 shedding should be considered in patients who receive BR therapy. This study involved multiple reactions and reactants, such as 4-(5-(Bis(2-chloroethyl)amino)-1-methyl-1H-benzo[d]imidazol-2-yl)butanoic acid (cas: 16506-27-7Related Products of 16506-27-7).

4-(5-(Bis(2-chloroethyl)amino)-1-methyl-1H-benzo[d]imidazol-2-yl)butanoic acid (cas: 16506-27-7) belongs to imidazole derivatives. The solubility of imidazoles in ethers is lower than that in alcohols and decreases with increasing chain length of the ethers . In contrast, the solubility of benzimidazoles in alcohols (C3鈥揅6) is higher than in water and generally decreases with a Imidazole has been usedin the lysis, wash and elution buffer for the purification of histidine tagged Sonic Hedgehog(shh-N) protein, in elution buffer in stepwise gradient for the purification of histidine tagged aldo keto reductases using nickel affinity chromatography, as a component of homogenization buffer for the purification of phagosomal compartments from dendritic cells.Related Products of 16506-27-7

Referemce:
Imidazole – Wikipedia,
Imidazole | C3H4N2 – PubChem

Phase 1 Study Evaluating Pharmacokinetics and Tolerability of Ofatumumab Combined With Bendamustine in Patients With Indolent B-Cell Non-Hodgkin鈥瞫 Lymphoma was written by Forero-Torres, Andres;Chandler, Jason Claud;Iyer, Swaminathan P.;Kanate, Abraham S.;Quinlan, Michelle;Hoever, Petra;Izquierdo, Miguel;Davis, Jaclyn;Madan, Sumit. And the article was included in Clinical Pharmacology in Drug Development in 2022.Name: 4-(5-(Bis(2-chloroethyl)amino)-1-methyl-1H-benzo[d]imidazol-2-yl)butanoic acid The following contents are mentioned in the article:

The pharmacokinetics (PK) and safety of ofatumumab and bendamustine alone and in combination were evaluated in patients with treatment-naive or relapsed indolent B-cell non-Hodgkin lymphoma (iNHL). Patients were randomly assigned to ofatumumab and bendamustine or ofatumumab alone. Ofatumumab PK concentration profiles and parameters were similar, alone or in combination with bendamustine. A decrease of 14% in the maximum observed plasma concentration (C_max) and 15% in the area under the plasma concentration-time curve (AUC) from time 0 to the last measurable concentration sampling time (AUC_last) was observed for ofatumumab coadministered with bendamustine, which was not considered clin. relevant. Bendamustine PK concentration profiles and parameters were similar with or without ofatumumab. The most frequent treatment-related adverse event was infusion-related reaction in 53% in the combination arm and 47% in the ofatumumab arm. No relevant drug-drug interaction was observed between ofatumumab and bendamustine. Ofatumumab alone or in combination with bendamustine had a manageable safety profile. This study involved multiple reactions and reactants, such as 4-(5-(Bis(2-chloroethyl)amino)-1-methyl-1H-benzo[d]imidazol-2-yl)butanoic acid (cas: 16506-27-7Name: 4-(5-(Bis(2-chloroethyl)amino)-1-methyl-1H-benzo[d]imidazol-2-yl)butanoic acid).

4-(5-(Bis(2-chloroethyl)amino)-1-methyl-1H-benzo[d]imidazol-2-yl)butanoic acid (cas: 16506-27-7) belongs to imidazole derivatives. Many natural products, especially alkaloids, contain the imidazole ring. These imidazoles share the 1,3-C3N2 ring but feature varied substituents. Imidazole also acts as a microtubule destabilizing agents and inhibits topoisomerase and Cytochrome P450 Family 26 Subfamily A Member 1 (CYP26A1) enzymes.Name: 4-(5-(Bis(2-chloroethyl)amino)-1-methyl-1H-benzo[d]imidazol-2-yl)butanoic acid

Referemce:
Imidazole – Wikipedia,
Imidazole | C3H4N2 – PubChem

LocoMMotion: a prospective, non-interventional, multinational study of real-life current standards of care in patients with relapsed and/or refractory multiple myeloma was written by Mateos, Maria-Victoria;Weisel, Katja;De Stefano, Valerio;Goldschmidt, Hartmut;Delforge, Michel;Mohty, Mohamad;Cavo, Michele;Vij, Ravi;Lindsey-Hill, Joanne;Dytfeld, Dominik;Angelucci, Emanuele;Perrot, Aurore;Benjamin, Reuben;van de Donk, Niels W. C. J.;Ocio, Enrique M.;Scheid, Christof;Gay, Francesca;Roeloffzen, Wilfried;Rodriguez-Otero, Paula;Broijl, Annemiek;Potamianou, Anna;Sakabedoyan, Caline;Semerjian, Maria;Keim, Sofia;Strulev, Vadim;Schecter, Jordan M.;Vogel, Martin;Wapenaar, Robert;Nesheiwat, Tonia;San-Miguel, Jesus;Sonneveld, Pieter;Einsele, Hermann;Moreau, Philippe. And the article was included in Leukemia in 2022.HPLC of Formula: 16506-27-7 The following contents are mentioned in the article:

Despite treatment advances, patients with multiple myeloma (MM) often progress through standard drug classes including proteasome inhibitors (PIs), immunomodulatory drugs (IMiDs), and anti-CD38 monoclonal antibodies (mAbs). LocoMMotion (ClinicalTrials.gov identifier: NCT04035226) is the first prospective study of real-life standard of care (SOC) in triple-class exposed (received at least a PI, IMiD, and anti-CD38 mAb) patients with relapsed/refractory MM (RRMM). Patients (N = 248; ECOG performance status of 0-1, 鈮? prior lines of therapy or double refractory to a PI and IMiD) were treated with median 4.0 (range, 1-20) cycles of SOC therapy. Overall response rate was 29.8% (95% CI: 24.2-36.0). Median progression-free survival (PFS) and median overall survival (OS) were 4.6 (95% CI: 3.9-5.6) and 12.4 mo (95% CI: 10.3-NE). Treatment-emergent adverse events (TEAEs) were reported in 83.5% of patients (52.8% grade 3/4). Altogether, 107 deaths occurred, due to progressive disease (n = 74), TEAEs (n = 19), and other reasons (n = 14). The 92 varied regimens utilized demonstrate a lack of clear SOC for heavily pretreated, triple-class exposed patients with RRMM in real-world practice and result in poor outcomes. This supports a need for new treatments with novel mechanisms of action. This study involved multiple reactions and reactants, such as 4-(5-(Bis(2-chloroethyl)amino)-1-methyl-1H-benzo[d]imidazol-2-yl)butanoic acid (cas: 16506-27-7HPLC of Formula: 16506-27-7).

4-(5-(Bis(2-chloroethyl)amino)-1-methyl-1H-benzo[d]imidazol-2-yl)butanoic acid (cas: 16506-27-7) belongs to imidazole derivatives. Imidazole is the basic core of some natural products such as histidine, purine, histamine and DNA based structures, etc. Among the different heterocyclic compounds, imidazole is better known due to its broad range of chemical and biological properties. Imidazole is incorporated into many important biological compounds. The most pervasive is the amino acid histidine, which has an imidazole side-chain. Histidine is present in many proteins and enzymes, e.g. by binding metal cofactors, as seen in hemoglobin.HPLC of Formula: 16506-27-7

Referemce:
Imidazole – Wikipedia,
Imidazole | C3H4N2 – PubChem

Cost drivers associated with diffuse large B-cell lymphoma (DLBCL) in Japan: A structural equation model (SEM) analysis was written by Tsutsue, Saaya;Makita, Shinichi;Yi, Jingbo;Crawford, Bruce. And the article was included in PLoS One in 2022.Electric Literature of C16H21Cl2N3O2 The following contents are mentioned in the article:

Diffuse large B-cell lymphoma (DLBCL) is an aggressive non-Hodgkin’s lymphoma of increasing prevalence in Japan. However, patients with relapsed or refractory disease to first line treatment (rrDLBCL) have been found to shoulder greater economic burden and have poor survival with subsequent lines of therapy. The relative impact of individual patient attributes on total medical cost among patients with rrDLBCL receiving second or third line (2L/3L) therapy was assessed. Structural equation modeling was used to identify potential cost drivers of total medical costs incurred by treatment and procedures in a Japanese retrospective claims database. From the database, rrDLBCL patients on 2L or 3L of treatment were grouped into resp. cohorts. The mean [median] (SD) total medical cost of care for the 2L cohort was 73,296.40 [58,223.11] (58,409.79) US dollars (USD) and 75,238.35 [60,477.31] (59,583.66) USD for the 3L cohort. The largest total effect on medical cost in both cohorts was length of hospital stay (LOS) (尾: 0.750 [95%CI: 0.728, 0.772] vs 尾: 0.762 [95%CI: 0.729, 0.794]). Length of hospital stay and potential heart disease complications due to line of treatment were the primary drivers of total cost for patients who had received at least 2L or 3L therapy for rrDLBCL. This study involved multiple reactions and reactants, such as 4-(5-(Bis(2-chloroethyl)amino)-1-methyl-1H-benzo[d]imidazol-2-yl)butanoic acid (cas: 16506-27-7Electric Literature of C16H21Cl2N3O2).

4-(5-(Bis(2-chloroethyl)amino)-1-methyl-1H-benzo[d]imidazol-2-yl)butanoic acid (cas: 16506-27-7) belongs to imidazole derivatives. The solubility of imidazoles in ethers is lower than that in alcohols and decreases with increasing chain length of the ethers . In contrast, the solubility of benzimidazoles in alcohols (C3鈥揅6) is higher than in water and generally decreases with a Imidazole has been usedin the lysis, wash and elution buffer for the purification of histidine tagged Sonic Hedgehog(shh-N) protein, in elution buffer in stepwise gradient for the purification of histidine tagged aldo keto reductases using nickel affinity chromatography, as a component of homogenization buffer for the purification of phagosomal compartments from dendritic cells.Electric Literature of C16H21Cl2N3O2

Referemce:
Imidazole – Wikipedia,
Imidazole | C3H4N2 – PubChem